This compound is a pharmaceutical intermediate featuring a complex structure with multiple stereocenters, containing an alcohol, aromatic rings, ether groups, and a heterocycle. Its high molecular weight and lipophilicity, along with significant hydrogen bond donor and acceptor capacity, indicate a role in the synthesis of specialized organic molecules for pharmaceutical manufacturing.
Portée du contenu: Les informations de cette page concernent l'identification chimique ainsi que les contextes d'approvisionnement industriel, de recherche et de production. Elles ne constituent ni une allégation thérapeutique, ni un avis médical, ni une notice d'utilisation médicamenteuse.
Approvisionnement ou fourniture de ce composé?
Publiez votre inventaire ou une demande d'achat
CAS 162849-95-8
1-((3R,5r,8r,9r,10s,13s,14s,17s)-3-hydroxy-3,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)ethanone
pharmaceutical intermediate
(alphaR,2R)-3,4-Dihydro-5-[(4-nitrophenyl)methyl]-alpha-phenyl-2H-pyrrole-2-methanol
pharmaceutical intermediate
Tert-butyl (R)-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-carboxylate
Pharmaceutical intermediate
4-(Piperidin-4-yl)benzonitrile--hydrogen chloride (1/1)
pharmaceutical intermediate
1,3-Thiazol-5-ylmethyl N-[(1S,2S,4S)-4-amino-1-benzyl-2-hydroxy-5-phenylpentyl]carbamate
pharmaceutical intermediate for protease inhibitors
tert-butyl N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-(1,3-thiazol-5-ylmethoxycarbonylamino)hexan-2-yl]carbamate
NURNDOWJCSUXHT-HVCNVCAESA-N
CC(C)(C)OC(=O)N[C@@H](CC1=CC=CC=C1)C[C@@H]([C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)O